Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 4/20 | 0.50 |
| ▸ | NOS2 | P35228 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21998957 | 0.88 | TAAR1 (0.41) | TAAR1NOS1NOS2KCNH2SMN1; SMN2 | |
| SCHEMBL23316581 | 0.84 | KCNH2 (0.53) | TAAR1NOS1NOS2KCNH2CYP2D6 | |
| SCHEMBL20313307 | 0.84 | TAAR1 (0.44) | TAAR1SMN1; SMN2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL30173447 | 0.83 | KCNH2 (0.73) | NOS1NOS2KCNH2SMN1; SMN2BACE1 | |
| SCHEMBL1563917 | 0.83 | KCNH2 (0.73) | NOS1NOS2KCNH2SMN1; SMN2BACE1 | |
| SCHEMBL8286835 | 0.83 | GRM5 (0.57) | TAAR1NOS1NOS2KCNH2SMN1; SMN2 | |
| SCHEMBL30201993 | 0.82 | CCR1 (0.52) | NOS1NOS2KCNH2SMN1; SMN2NOS3 | |
| SCHEMBL24916774 | 0.82 | CCR1 (0.52) | NOS1NOS2KCNH2SMN1; SMN2NOS3 | |
| SCHEMBL10144469 | 0.80 | KCNH2 (0.54) | NOS1NOS2KCNH2SMN1; SMN2NOS3 | |
| SCHEMBL29596752 | 0.80 | TAAR1 (0.74) | TAAR1NOS1NOS2HRH3DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3572401-B1 | ASK1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-11021486-B2 | Coumarin-like cyclic compound as MEK inhibitor and use thereof | CSTONE PHARMACEUTICALS (KY) | 2021-06-01 | — | — | US | disclosed |
| US-20200148695-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021486-B2 | Coumarin-like cyclic compound as MEK inhibitor and use thereof | MAP3K11, MAP3K15, MAP3K20 | TAAR1 3897/4885NOS1 1517/4885NOS2 2008/4885 |
| US-20200148695-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | MAP3K11, MAP3K15, MAP3K20 | TAAR1 3897/4885NOS1 1517/4885NOS2 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.